# A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

> **NCT02426125** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 530 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Docetaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02426125
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-13
- **Primary completion:** 2017-04-21
- **Final completion:** 2022-07-26
- **Target enrollment:** 530 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02426125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02426125, "A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02426125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*